Literature DB >> 32436682

Economic burden of osteoporotic fractures in US managed care enrollees.

Setareh A Williams1, Benjamin Chastek, Kevin Sundquist, Sergio Barrera-Sierra, Deane Leader, Richard J Weiss, Yamei Wang, Jeffrey R Curtis.   

Abstract

OBJECTIVES: To examine healthcare resource utilization (HRU) and costs in a population of managed care enrollees who experienced an osteoporotic fracture. STUDY
DESIGN: Retrospective cohort study using the Optum Research Database (January 2007 to May 2017).
METHODS: All-cause and osteoporosis-related HRU and costs were analyzed in patients 50 years and older with a qualifying index fracture and continuous enrollment with medical and pharmacy benefits for 12 months preindex (baseline period).
RESULTS: Of 1,841,263 patients with fractures during the identification period, 302,772 met eligibility criteria. Two-thirds (66.6%) were 65 years and older, 71.6% were women, and 41.2% were commercial (not Medicare Advantage) enrollees. The most common fracture sites were spine (21.9%), radius/ulna (19.5%), and hip (13.7%). Mean (SD) total all-cause healthcare cost was $34,855 ($56,094), with most paid by health plans ($31,863 [$55,025]) versus patients ($2992 [$2935]). Most healthcare costs were for medical ($31,766 [$54,943]) versus pharmacy ($3089 [$6799]) services. Approximately 75% of patients received rehabilitation services (mean [SD] cost = $18,025 [$41,318]). Diagnosis of index fracture during an inpatient stay versus an outpatient visit (cost ratio, 2.16; 95% CI, 2.13-2.19) and fractures at multiple sites (cost ratio, 1.23; 95% CI, 1.21-1.26) were the leading predictors of cost. Kaplan-Meier estimated cumulative second-fracture rates were 6.6% at 1 year, 12.3% at 2 years, 16.9% at 3 years, and 20.9% at 4 years after index fracture.
CONCLUSIONS: These findings suggest a significant economic burden associated with fractures, including a high total all-cause cost of care. Early identification and treatment of patients at high risk of fractures are of paramount importance to reduce fracture risk and associated healthcare costs.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32436682     DOI: 10.37765/ajmc.2020.43156

Source DB:  PubMed          Journal:  Am J Manag Care        ISSN: 1088-0224            Impact factor:   2.229


  14 in total

1.  Cost Effectiveness of Dapagliflozin Added to Standard of Care for the Management of Diabetic Nephropathy in the USA.

Authors:  Tadesse M Abegaz; Vakaramoko Diaby; Fatimah Sherbeny; Askal Ayalew Ali
Journal:  Clin Drug Investig       Date:  2022-05-25       Impact factor: 2.859

2.  A timeseries analysis of the fracture callus extracellular matrix proteome during bone fracture healing.

Authors:  Christopher B Erickson; Ryan Hill; Donna Pascablo; Galateia Kazakia; Kirk Hansen; Chelsea Bahney
Journal:  J Life Sci (Westlake Village)       Date:  2021-12

3.  Osteoporosis management and secondary fragility fracture rates in patients with multiple sclerosis: a matched cohort study.

Authors:  Bailey J Ross; Austin J Ross; Olivia C Lee; Timothy L Waters; McCayn M Familia; William F Sherman
Journal:  Osteoporos Int       Date:  2022-06-07       Impact factor: 5.071

Review 4.  Discontinuation of bisphosphonates in seniors: a systematic review on health outcomes.

Authors:  Marianne Lamarre; Martine Marcotte; Danielle Laurin; Daniela Furrer; Isabelle Vedel; André Tourigny; Anik Giguère; Pierre-Hugues Carmichael; Rosa Martines; José Morais; Edeltraut Kröger
Journal:  Arch Osteoporos       Date:  2021-09-15       Impact factor: 2.617

5.  Secular Trends in the Pharmacologic Treatment of Osteoporosis and Malignancy-Related Bone Disease from 2009 to 2020.

Authors:  Sara Jane Cromer; Kristin M D'Silva; Elaine W Yu; Joan Landon; Rishi J Desai; Seoyoung C Kim
Journal:  J Gen Intern Med       Date:  2021-06-07       Impact factor: 6.473

Review 6.  Barriers and Resources to Optimize Bone Health in Orthopaedic Education: Own the Bone (OTB): Bone Health Education in Residency.

Authors:  Eli B Levitt; David A Patch; Brent A Ponce; Afshin E Razi; Stephen L Kates; Joshua C Patt
Journal:  JB JS Open Access       Date:  2021-10-08

7.  Chronic liver disease and cirrhosis increase morbidity in geriatric patients treated surgically for hip fractures: analysis of the US Nationwide Inpatient Sample.

Authors:  Feng-Jen Tseng; Guo-Hau Gou; Sheng-Hao Wang; Jia-Fwu Shyu; Ru-Yu Pan
Journal:  BMC Geriatr       Date:  2022-02-23       Impact factor: 3.921

8.  Outcomes post fragility fracture among members of an integrated healthcare organization.

Authors:  Annette L Adams; Denison S Ryan; Bonnie H Li; Setareh A Williams; Yamei Wang; Richard J Weiss; Dennis M Black
Journal:  Osteoporos Int       Date:  2021-10-23       Impact factor: 4.507

9.  Development and validation of a one year predictive model for secondary fractures in osteoporosis.

Authors:  Setareh A Williams; Susan L Greenspan; Tim Bancroft; Benjamin J Chastek; Yamei Wang; Richard J Weiss; Nick Pyrih; Hily Nichols; Jane A Cauley
Journal:  PLoS One       Date:  2021-09-27       Impact factor: 3.240

10.  Comparison of efficacy and safety of Chinese patent medicine in the treatment of postmenopausal osteoporosis: A protocol for systematic review and network meta-analysis.

Authors:  Hongqiang An; Jifeng Zhao; Jiahao Wang; Chuancheng Li; Zhenyuan Jiang; Junpeng Yao; Xiao Zhang; Jianlin Wu
Journal:  Medicine (Baltimore)       Date:  2020-10-16       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.